Lumos Pharma (LUMO)
(Delayed Data from NSDQ)
$3.93 USD
+0.01 (0.26%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.90 -0.03 (-0.76%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Lumos Pharma, Inc [LUMO]
Reports for Purchase
Showing records 1 - 20 ( 77 total )
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Patent Protection For Novel Formulation of LUM-201 Extended to 2042
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
4Q23 Results; Pivotal Phase 3 Study for LUM-201 Could Commence in 4Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Recap of KOL Event on Phase 2 OraGrowtH210 and OraGrowtH212 Trials
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
3Q23 Results; LUM-201 Phase 2 Data Hits All Primary and Secondary Endpoints in PGHD
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
New Data and Analysis From OraGrowtH212 Trial Presented at 2023 ESPE Annual Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Highlights From KOL Event on Pediatric Growth Hormone Deficiency and LUM-201
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
2Q23 Results; Data From Two Phase 2 Studies of LUM-201 Expected in 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Recap of Virtual KOL Event Highlighting LUM-201 Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Additional OraGrowtH212 Interim Analysis Data Presented At the 2023 Annual Meeting of the Pediatric Endocrine Society
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
1Q23 Results; Primary Outcome Data From OraGrowtH210 and OraGrowtH212 Anticipated in 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Additional Positive Data From the OraGrowtH212 Study Released at IMPE
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
4Q22 Results; OraGrowtH Phase 2 Trials Primary Outcome Data Expected in 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Recap of KOL Event on LUM-201 Interim Data Released in November
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
3Q22 Results; Cloudy Interim Data for LUM-201 Could Improve as Baseline Characteristics Become More Comparable
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
2Q22 Results; Two Phase 2 Readouts for LUM-201 Expected by YE22
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
1Q22 Results; OraGrowtH210 and OraGrowtH212 Interim Data Expected by YE22
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E